PA
GTHX

Perceptive Advisors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Perceptive Advisors’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-15,702
Closed -$358K – 123
2019
Q3 		$358K Buy
+15,702
New +$495K 0.01% 104
2018
Q4 		– Sell
-14,055
Closed -$735K – 127
2018
Q3 		$735K Hold
14,055
– – 0.02% 97
2018
Q2 		$611K Buy
+14,055
New +$602K 0.02% 105

Other funds holding GTHX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Perceptive Advisors's GTHX Position: Q4 2019 in Review

Perceptive Advisors sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q4 2019, closing a stake of 15,702 shares — an estimated $358K sold.

Perceptive Advisors first reported a position in GTHX in Q2 2018 and held it in 3 quarters. The position peaked at $735K in Q3 2018. 98 funds tracked by Wall St. Rank hold GTHX as of Q4 2019.

  • Perceptive Advisors reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Perceptive Advisors sold 15,702 G1 Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $358K.
  • Perceptive Advisors first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2018 and held it in 3 quarters.
  • Perceptive Advisors's G1 Therapeutics, Inc. Common Stock position peaked at $735K in Q3 2018.
  • 98 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Perceptive Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.